Individual ER, PR, and HER2 expression scores with recurrence score® (RSTM) generated from a validated algorithm that compares expression levels of 16 cancer-related genes to the expression of five housekeeping control reference genes have been used to predict the risk of disease recurrence within 10 years after treatment [27]. The gene discussed is ERBB2; the disease is cancer.